Emergent Biosolutions, Inc. (EBS) is a publicly traded Healthcare sector company. As of May 21, 2026, EBS trades at $8.21 with a market cap of $419.48M and a P/E ratio of -58.21. EBS moved +1.30% today. Year to date, EBS is -36.58%; over the trailing twelve months it is +17.44%. Its 52-week range spans $4.02 to $14.06. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces EBS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded EBS stock?
Recent politician trading activity in EBS includes disclosures from Steve Cohen. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
EBS Key Metrics
Key financial metrics for EBS
Metric
Value
Price
$8.21
Market Cap
$419.48M
P/E Ratio
-58.21
EPS
$-0.14
Dividend Yield
0.00%
52-Week High
$14.06
52-Week Low
$4.02
Volume
468
Avg Volume
0
Revenue (TTM)
$676.80M
Net Income
$-8.60M
Gross Margin
54.24%
Congressional Trades in EBS
Steve Cohen sale EBS on Dec 11, 2024 (amount: $15.00K).
Recent politician trading activity in EBS includes disclosures from Steve Cohen. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in EBS?
Yes. Rallies tracks politician and congressional stock disclosures for EBS, including reported purchases, sales, dates, owners, and trade amounts when available.
Is EBS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for EBS. It does not provide personalized investment advice.
